Email this article Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer
- Authors: Bespalov V.G.1,2, Vyshinskaya E.A.1, Vasil’eva I.N.1,2, Semenov A.L.1,2, Maidin M.A.1, Barakova N.V.2, Stukov A.N.1
-
Affiliations:
- Research Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, I. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation
- International Research Centre “Biotechnologies of the Third Millennium”, ITMO University (St. Petersburg National Research University of Information Technologies, Mechanics and Optics
- Issue: Vol 162, No 3 (2017)
- Pages: 383-386
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/238232
- DOI: https://doi.org/10.1007/s10517-017-3621-5
- ID: 238232
Cite item
Open Access
Access granted
Subscription Access
Abstract
Antitumor efficiencies of cytostatics dioxadet, cisplatin, mitomycin C, melphalan, and paclitaxel after a single intraperitoneal or intravenous injection in doses of 1.5, 4, 1.5, 2, and 5 mg/kg, respectively, were studied on the model of transplanted ovarian tumor in 124 rats. The antitumor effects were evaluated by the increase in median survival. Dioxadet, cisplatin, and melphalan injected intraperitoneally significantly prolonged the lifespan median – by 79, 88, and 114%, respectively, and were in fact ineffective, when injected intravenously. Intraperitoneal mitomycin C prolonged lifespan median by just 35%, intravenous – by 152%. Paclitaxel injected intraperitoneally and intravenously prolonged the lifespan median by 45 and 81%, respectively.
About the authors
V. G. Bespalov
Research Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, I. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation; International Research Centre “Biotechnologies of the Third Millennium”, ITMO University (St. Petersburg National Research University of Information Technologies, Mechanics and Optics
Email: iravasilyeva@hotmail.com
Russian Federation, St. Petersburg; St. Petersburg
E. A. Vyshinskaya
Research Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, I. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation
Email: iravasilyeva@hotmail.com
Russian Federation, St. Petersburg
I. N. Vasil’eva
Research Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, I. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation; International Research Centre “Biotechnologies of the Third Millennium”, ITMO University (St. Petersburg National Research University of Information Technologies, Mechanics and Optics
Author for correspondence.
Email: iravasilyeva@hotmail.com
Russian Federation, St. Petersburg; St. Petersburg
A. L. Semenov
Research Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, I. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation; International Research Centre “Biotechnologies of the Third Millennium”, ITMO University (St. Petersburg National Research University of Information Technologies, Mechanics and Optics
Email: iravasilyeva@hotmail.com
Russian Federation, St. Petersburg; St. Petersburg
M. A. Maidin
Research Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, I. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation
Email: iravasilyeva@hotmail.com
Russian Federation, St. Petersburg
N. V. Barakova
International Research Centre “Biotechnologies of the Third Millennium”, ITMO University (St. Petersburg National Research University of Information Technologies, Mechanics and Optics
Email: iravasilyeva@hotmail.com
Russian Federation, St. Petersburg
A. N. Stukov
Research Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, I. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation
Email: iravasilyeva@hotmail.com
Russian Federation, St. Petersburg
